{"entity":{"id":"imagion-biosystems","kind":"company","name":"Imagion Biosystems","aka":["Imagion Biosystems, Ltd.","Imagion Biosystems, Inc."],"tldr":"Imagion Biosystems makes an MRI contrast agent of tiny magnetic particles that stick to a cancer marker, so a scan can show whether HER2-positive breast cancer has spread to the lymph nodes without a biopsy.","summary":"Imagion Biosystems, Ltd., registered at Bourke Street, Melbourne, with a US subsidiary, Imagion Biosystems, Inc., in Incline Village, Nevada, develops MagSense molecular MRI: bio-safe magnetic nanoparticles linked to targeting molecules that bind cancer biomarkers. Its lead agent, the MagSense HER2 Imaging Agent (MSH2IA), completed a multi-site phase 1 study (enrolment closed in July 2023) in HER2-positive breast cancer to assess spread to axillary lymph nodes, and the company says it detects tumour signals as small as 1 to 2 mm; a folate receptor agent for ovarian cancer is preclinical. The company identifies itself as IBX and publishes ASX announcements. Its first registered cancer trial on ClinicalTrials.gov, NCT07885683, a phase 1b/2 study of MSH2IA with MRI in HER2-positive breast cancer, was posted in October 2026; no earlier study is registered on ClinicalTrials.gov under this sponsor name.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://imagionbiosystems.com/"},{"label":"Investor site","url":"https://investor.imagionbiosystems.com/"},{"label":"ClinicalTrials.gov: phase 1b/2 trial of MSH2IA (NCT07885683)","url":"https://clinicaltrials.gov/study/NCT07885683"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":["imaging","diagnostics"],"technologies":["mri"],"targets":["her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The ticker IBX and an ASX listing are inferred from the company's investor site, which lists 'ASX Announcements' and refers to the company as IBX; an exchange-and-ticker statement was not found in the text read. Founding year not stated. The 1 to 2 mm detection claim is the company's own. Read on 29 October 2026."],"hq":"Melbourne","country":"AU","companyType":"imaging","website":"https://imagionbiosystems.com/","ticker":"IBX","stage":"public","investors":[],"funding":[]},"route":"/companies/imagion-biosystems/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"imaging","kind":"section","name":"Imaging","route":"/fronts/imaging/"}],"technology":[{"id":"mri","kind":"technology","name":"MRI","route":"/technologies/mri/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}]}}